Vancouver, British Columbia–(Newsfile Corp. – December 1, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that Dr. Henry Kranzler…


Previous articleSilo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide
Next articlePsychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS; SSRI Psilocybin Interaction Study